AN ACTIVE SITE PTPN2/N1 SMALL MOLECULE INHIBITOR PROMOTES ANTI-TUMOR EFFICACY BY SENSITIZING TUMOR CELLS TO INFLAMMATORY SIGNALS AND ENHANCING IMMUNE CELL ACTIVITY

被引：1
|
作者：
McGuire, Kathleen [1 ]
Baumgartner, Christina [1 ]
Backus, Carey [1 ]
Mathew, Rebecca [1 ]
Klinge, Kelly [1 ]
Klahn, Joseph [1 ]
Geda, Prasanthi [2 ]
Halliwill, Kyle [1 ]
Aguado, Jacqueline [1 ]
Mu, Liang [1 ]
Duggan, Ryan [1 ]
Hrusch, Cara [1 ]
Farney, Elliot [1 ]
Xiong, Zhaoming [1 ]
Bulic, Marinka [1 ]
Trusk, Patricia [1 ]
Lasko, Loren [1 ]
Ebrahimi-Nik, Hakimeh [3 ]
Yates, Kathleen [3 ]
Manguso, Robert [3 ]
Hamel, Keith [1 ]
Paddock, Marcia [4 ]
Frost, Jennifer [1 ]
Kym, Philip [1 ]
机构：
[1] Abbvie Inc, N Chicago, IL USA
[2] Bristol Myers Squibb, Summit, NJ USA
[3] Broad Inst MIT & Harvard, Cambridge, MA USA
[4] Calico Life Sci LLC, San Francisco, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.1365
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1365
引用
收藏
页码：A1416 / A1416
页数：1
相关论文
共 16 条
  • [1] A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
    Liang, Shuwei
    Tran, Eric
    Du, Xin
    Dong, Jiajun
    Sudholz, Harrison
    Chen, Hao
    Qu, Zihan
    Huntington, Nicholas D.
    Babon, Jeffrey J.
    Kershaw, Nadia J.
    Zhang, Zhong-Yin
    Baell, Jonathan B.
    Wiede, Florian
    Tiganis, Tony
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [2] A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
    Shuwei Liang
    Eric Tran
    Xin Du
    Jiajun Dong
    Harrison Sudholz
    Hao Chen
    Zihan Qu
    Nicholas D. Huntington
    Jeffrey J. Babon
    Nadia J. Kershaw
    Zhong-Yin Zhang
    Jonathan B. Baell
    Florian Wiede
    Tony Tiganis
    Nature Communications, 14
  • [3] Discovery of potent and selective inhibitors of the protein tyrosine phosphatases PTPN2 and PTPN1 to trigger anti-tumor immunity through sensitization of tumor cells and activation of immune cells
    Pervolaraki, Kalliopi
    Katkeviciute, Egle
    Lambin, Dominique
    Boland, Sandro
    Kilonda, Amuri
    Pericolle, Vincent
    Nijs, Marnik
    Haeck, Wanda
    Metzger, Kristine
    Klaassen, Hugo
    Marchand, Arnaud
    Chaltin, Patrick
    Versele, Matthias
    Spalinger, Marianne
    Scharl, Michael
    CANCER RESEARCH, 2023, 83 (07)
  • [4] ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killing
    Baumgartner, Christina K.
    Paddock, Marcia N.
    Frost, Jennifer M.
    Hamel, Keith M.
    McGuire, Kathleen A.
    Halliwill, Kyle
    Xiong, Zhaoming
    Mu, Liang
    Klinge, Kelly
    Geda, Prasanthi
    Aguado, Jaqueline
    Bulic, Marinka
    Farney, Elliot P.
    Yates, Kathleen B.
    Manguso, Robert T.
    Beauregard, Clay
    Kym, Philip R.
    CANCER RESEARCH, 2022, 82 (12)
  • [5] A novel small molecule inhibitor of ENPP1 promotes T and NK cell activation and enhances anti-tumor efficacy in combination with immune checkpoint blockade therapy
    Yoon, Pyoung Oh
    Kim, Juhyeon
    Lee, A-Ram
    Son, Eunji
    Lee, Young Cheol
    Jung, Eunmi
    Kim, HyeongRae
    Lee, YeonHee
    Park, Soeun
    Lee, Dae-Yon
    Chung, Chul-Woong
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity
    Borodovsky, Alexandra
    Barbon, Christine M.
    Wang, Yanjun
    Ye, Minwei
    Prickett, Laura
    Chandra, Dinesh
    Shaw, Joseph
    Deng, Nanhua
    Sachsenmeier, Kris
    Clarke, James D.
    Linghu, Bolan
    Brown, Giles A.
    Brown, James
    Congreve, Miles
    Cheng, Robert K. Y.
    Dore, Andrew S.
    Hurrell, Edward
    Shao, Wenlin
    Woessner, Richard
    Reimer, Corinne
    Drew, Lisa
    Fawell, Stephen
    Schuller, Alwin G.
    Mele, Deanna A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [7] The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity
    Xuan, Yi-Fei
    Lu, Shan
    Ou, Ying-Jie
    Bao, Xu-Bin
    Huan, Xia-Juan
    Song, Shan-Shan
    Miao, Ze-Hong
    Wang, Ying-Qing
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 716
  • [8] BCL-2 inhibitor APG-2575 promotes anti-tumor efficacy of immune checkpoint blockade through converting tumor-associated macrophages into M1 phenotype in non-small cell lung cancer.
    Luo, Fan
    Lu, Fei Teng
    Qiu, Miao Zhen
    Pan, Wen Tao
    Zhang, Lin
    Zhao, Hong Yun
    Zhang, Li
    Yang, Da Jun
    CANCER RESEARCH, 2021, 81 (13)
  • [9] BCL-2 inhibitor APG-2575 promotes anti-tumor immunity through converting tumor-associated macrophages into M1 phenotype in non-small cell lung cancer
    Luo, Fan
    Lu, Fei-teng
    Qiu, Miao-zhen
    Pan, Wen-tao
    Zhang, Lin
    Zhao, Hong-yun
    Zhang, Li
    Yang, Da-jun
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Combination of an ERK1/2 inhibitor (LY3214996) with VEGFR-2 inhibitor enhances anti-tumor activity in KRAS mutant non-small cell lung cancer
    Wu, Wenjuan
    Bhagwat, Shripad V.
    Jones, Bonita D.
    Swearingen, Michelle L.
    Falcon, Beverly L.
    McMillen, William T.
    Joseph, Sajan
    Buchanan, Sean
    Peng, Sheng-Bin
    Reinhard, Christoph
    Tiu, Ramon V.
    CANCER RESEARCH, 2018, 78 (13)
12